BioSpace News Archive

Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing or monetizing promising therapeutic products and product candidates, today announced that Lindsay A. Rosenwald, M.D., Chairman, President and Chief Executive Officer, will present a corporate overview at the H.C. Wainwright 25th Annual Global Investment Conference on Tuesday, September 12, 2023, at 11:30 a.m. ET.

Palisade Bio, Inc. is announcing that it has entered into definitive agreements with institutional investors for the purchase of 2,339,398 shares of common stock for gross proceeds of $1,965,094.32 in a registered direct offering.

Procaps Group, S.A., a leading integrated LatAm healthcare and pharmaceutical services company, announced that it has entered into an agreement with BDR Pharmaceuticals International Pvt. Limited for 27 oncology molecules for Latin America, including 20 TKIs.

Jaguar today announced that Karen Brunke, PhD, the company’s EVP of Corporate and Business Development, has become a member of the Biotechnology Innovation Organization’s (BIO) Rare Disease and Orphan Drugs Committee.

Nexcella, Inc. today announced that Nexcella NXC-201 clinical data will be presented by Ilya Rachman MD PhD and Gabriel Morris at the Healthcare Trailblazers Private Company Conference Thursday, October 26, 2023.

The National Comprehensive Cancer Network announced the publication of a new supportive care patient guideline focused on preventing and treating cancer-associated blood clots, also known as venous thromboembolism.

PDO MAX, Inc., a woman-owned aesthetics medical device company based in the United States, introduces its third innovation for 2023. Shaping up to be the most exciting year in the company’s history, our latest offering is the Glowpin serum infusion system, which combines a multi-needle stimulator with an airless pump.

Sorrento Therapeutics, Inc. (OTC: SRNEQ, “Sorrento”) announced today positive Phase 2a top-line clinical trial results for the RTX program.

Eminence Biotechnology Co., Ltd. is delighted to announce that its state-of-the-art facility for the commercial production of cell culture media is now fully operational.

Avidity Biosciences, Inc. announced that it is joining with patient communities to raise awareness during National Muscular Dystrophy Awareness Month, an annual observance that takes place every September to support families across the U.S. who are impacted by neuromuscular diseases.